ischemic cerebrovascular disorder (ICD) patients and ischemic heart disease (IHD) patients
Conditions
Interventions
None listed
Sponsors
Daiichi Sankyo Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (Time of patient enrollment) Phase A 2015, Phase B 2017, Phase C 2019 (ICD cohort) 1.Patients who received antiplatelet agents during the inclusion period of each phase. The index date is the start date of prescription. 2.Patients with a diagnosis of imaging and cerebral infarction on the index date. (IHD cohort) 1.Patients with a procedure code of percutaneous coronary intervention (PCI) during the inclusion period of each phase. The index date is the first date of PCI. 2.Patients who received antiplatelet agents the index date.
Exclusion criteria
Exclusion criteria: (ICD cohort) 1.Patients with antiplatelet prescriptions during baseline period (between 5 months prior to the index date and the index date). 2.Patients with anticoagulant prescriptions between the start of baseline period and the end of the observation period. 3.Patients with indication for anticoagulation therapy (medical history of atrial fibrillation, persistent or paroxysmal atrial fibrillation, and prosthetic heart valve placement). (IHD cohort) 1.Patients with antiplatelet prescriptions between the start of baseline period and 2 weeks prior to the index date. 2.Patients with anticoagulant prescriptions between the start of baseline period and the end of the observation period. 3.Patients with indication for anticoagulation therapy (medical history of atrial fibrillation, persistent or paroxysmal atrial fibrillation, and prosthetic heart valve placement).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prescription status of antiplatelet agents at the index date and every three months for two years after the index date (The proportion of prescribing antiplatelet agents, dual antiplatelet therapy (DAPT) and single antiplatelet therapy (SAPT)) | — |
Countries
Japan
Contacts
Public ContactMasako Sugimoto
Daiichi Sankyo Co., Ltd. Primary Medical Science Department
Outcome results
None listed